Trastuzumab Kit containing 1 vial Trastuzumab (nominal content: 440 mg); 1 20 mL multiple dose vi...

FDA Drug Recall #D-135-2013 — Class I — July 30, 2012

Recall Summary

Recall Number D-135-2013
Classification Class I — Serious risk
Date Initiated July 30, 2012
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Genentech Inc
Location South San Francisco, CA
Product Type Drugs
Quantity 2,140 kits

Product Description

Trastuzumab Kit containing 1 vial Trastuzumab (nominal content: 440 mg); 1 20 mL multiple dose vial Bacteriostatic Water for Injection, USP (1.1% benzyl alcohol), Manufactured by Hospira, Inc., for Genentech, Inc., South San Francisco, CA 94080-4990, NDC 50242-903-69; and 1 Reconstitution Instructions per kit; Investigation Use only, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080-4990.

Reason for Recall

Presence of Particulate Matter: One lot of Bacteriostatic Water for Injection, USP diluent vials that were packed with Trastuzumab Kits for investigational use has the potential to contain glass particulates.

Distribution Pattern

Nationwide

Lot / Code Information

Lot #: 454138, Exp 07/14 (containing Trastuzumab Lot #: 886618, Exp 12/14; and Bacteriostatic Water for Injection, USP Lot #: 08-368-DK-01, Exp 07/14)

Other Recalls from Genentech Inc

Recall # Classification Product Date
D-0025-2023 Class III Susvimo (ranibizumab injection), 100mg/mL, sold... Oct 18, 2022
D-0650-2021 Class II Xolair (omalizumab) Injection, 150 mg/1 mL, 1 p... Jun 9, 2021
D-0357-2021 Class III Evrysdi (risdiplam) for oral solution, 60 mg/80... Apr 20, 2021
D-087-2013 Class II Nutropin AQ NuSpin 20 (somatropin (rDNA origin)... Sep 20, 2012
D-088-2013 Class II Nutropin AQ NuSpin 10 (somatropin (rDNA origin)... Sep 20, 2012

Frequently Asked Questions

Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.